Nanoscope Therapeutics Achieves Critical FDA Milestone for MOGENRY to Treat Severe Vision Loss

Nanoscope Therapeutics Achieves a Pivotal Milestone with FDA Acceptance of MOGENRY

Nanoscope Therapeutics, Inc., a biopharmaceutical venture dedicated to pioneering innovative therapies for vision impairment, has marked a pivotal occasion in the field of ophthalmology. On September 9, 2026, the U.S. Food and Drug Administration (FDA) confirmed its acceptance and formal filing of the Biologics License Application (BLA) for MOGENRY (sonpiretigene isteparvovec, MCO-010). This groundbreaking optogenetic therapy is designed specifically for patients suffering from retinitis pigmentosa (RP), a condition causing severe vision loss.

Significance of MOGENRY

This BLA represents a significant step forward, as MOGENRY stands out as a potential first gene-agnostic treatment for individuals grappling with substantial visual impairments due to RP. The importance of the treatment cannot be overstated—it promises a one-time, in-office procedure that could change lives for many who currently find themselves with no viable therapy options.

According to CEO Sulagna Bhattacharya, the acceptance of the BLA is not just a regulatory milestone; it embodies hope for the RP community. “The robust results we saw in our RESTORE clinical study, coupled with the long-term follow-up data from REMAIN, instill confidence in our pursuit of new standards of care,” stated Bhattacharya, emphasizing the therapy's life-altering potential.

Clinical Study Results

The efficacy of MOGENRY is strongly backed by impressive results from the pivotal Phase 1/2a trial as well as the RESTORE Phase 2b/3 trial, which was meticulously designed to evaluate its effectiveness and safety. RESTORE's outcomes were compelling, revealing significant improvements in visual acuity at 52 and 76 weeks post-treatment. Notably, the treatment was well-tolerated, with no serious adverse effects reported—an encouraging sign for future applications.

Dr. Allen C. Ho, a leading figure in retinal studies and Nanoscope's Chief Medical Advisor, elaborated on the transformative nature of MOGENRY. “Restoring vision is the paramount challenge in the realm of gene therapy, and MOGENRY is making great strides,” he remarked. This innovative treatment circumvents the common necessity for genetic screening and invasive surgical techniques, thereby facilitating broader adoption across community medical practices.

The Broader Impact of Retinitis Pigmentosa

Retinitis pigmentosa is a complex and progressive hereditary disorder leading to the degeneration of photoreceptor cells, ultimately resulting in significant vision loss and, for many, total blindness. It's associated with over 1,000 mutations across various genes and is considered one of the leading causes of blindness among working-age adults in the United States. An estimated 100,000 individuals in the U.S. are affected, with a significant portion becoming legally blind by age 60.

Unfortunately, the current slow pace of advancements in gene therapies for RP highlights the critical need for effective treatments. With MOGENRY, Nanoscope Therapeutics aims not only to address this unmet need but also to usher in a new era of retinal therapies that could further facilitate vision restoration.

Innovative Technology Behind MOGENRY

MOGENRY utilizes Nanoscope's unique multi-characteristic opsin (MCO) technology, developed after over a decade of dedicated research and evaluation. The therapy is designed to deliver a genetically engineered synthetic opsin directly to the healthy retinal cells, rendering them light-sensitive and allowing patients to regain some visual function despite the loss of photoreceptor cells.

Dr. SriniVas Sadda, an esteemed ophthalmology expert, has been impressed with MOGENRY's long-term effectiveness. “The evidence supporting sustained benefits over the years positions MOGENRY as a standout contender in one-time treatments for retinal degeneration,” he asserted.

The Road Ahead for Nanoscope

Moving forward, Nanoscope Therapeutics intends to collaborate closely with the FDA during the thorough review process of its BLA. The company is also progressing with trials for other retinal degenerative conditions, such as Stargardt disease, further reflecting its commitment to expanding the therapeutic landscape for vision restoration.

In summary, the FDA's acceptance of Nanoscope's BLA for MOGENRY signifies a groundbreaking leap toward a future where patients with severe vision loss may regain their sight, presenting hope not only for individuals affected by retinitis pigmentosa but also for the broader field of ophthalmic gene therapy.